Iph4102-201

Web13 okt. 2016 · IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed to trigger killing of CTCL cancer cells, an orphan disease. This group of rare cutaneous lymphomas of T...

Innate Pharma : RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 …

Web29 okt. 2015 · IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2024 Aug;20 (8):1160-1170. doi: 10.1016/S1470-2045 (19)30320-1. Epub 2024 Jun 25. Study record dates Web29 jan. 2024 · IPH4102 is Innate Pharma’s wholly-owned first-in-class anti-KIR3DL2 antibody, developed for the treatment of T-cell lymphoma. Fast Track is a process designed to facilitate the development and expedite the regulatory review of investigational drugs to treat serious conditions and fill an unmet medical need. fish eat bread https://ourmoveproperties.com

IPH4102, a first-in-class anti-KIR3DL2 monoclonal ... - ScienceDirect

Web15 jun. 2024 · IPH4102 is Innate Pharma’s wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells. 25 patients, with a median age of 71 years old and a median number of four prior systemic treatments, were evaluable for safety (10 dose levels: 0.0001 to 10 mg/kg). Web12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der … WebArms in the two indications will consist of two cohorts each and will investigate IPH4102 in KIR3DL2 expressing and non-expressing patients. The trial’s primary endpoint is objective response rate and key secondary measures include treatment emergent adverse events, quality of life, overall response rate, progression-free survival, and overall survival. canada background

Innate Pharma Announces Worldwide Exclusive License with …

Category:IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in …

Tags:Iph4102-201

Iph4102-201

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in …

Web15 jun. 2024 · About IPH4102: IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T... Web• Initiation of IPH4102 , an international, openTELLOMAK -label, multicohort Phase II - study evaluating the efficacy and safety of IPH4102 in patient populations larger expressing KIR3DL2, including peripheral T cell lymphoma (PTCL). TELLOMAK is planned to recruit up to 250 patients, with IPH4102 evaluated as a single agent in

Iph4102-201

Did you know?

WebBrief Title: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Official Title: TELLOMAK: T-cell Lymphoma Anti- KIR3DL2 Therapy . … WebSézary syndrome (SS), the most aggressive form of cutaneous T-cell lymphoma (CTCL), is characterized by a high expression of the KIR3DL2 receptor. Speaking f...

Web3 dec. 2024 · innate pharma announces updated results that support advancement of iph4102 in refractory sÉzary syndrome at the american society of hematology 2024 annual meeting differentiating... march 26, 2024 WebThe EU Clinical Trials Register currently displays 43281 clinical trials with a EudraCT protocol, of which 7159 are clinical trials conducted with subjects less than 18 years old. …

Web6 dec. 2024 · In this trial, IPH4102 is evaluated alone and in combination with chemotherapy in patients with advanced TCL. TELLOMAK is expected to recruit up to 250 patients, with … Web20 mei 2016 · IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody (mAb). It depletes selectively KIR3DL2-expressing cells. Its modes of action include Antibody-Dependent Cell-Cytoxicity (ADCC) and –Phagocytosis (ADCP). IPH4102 has potent efficacy in non-clinical models, in particular ex vivo autologous assays using primary CTCL cells.

Web30 okt. 2014 · IPH4102 was effective in autologous killing assays in which it induces NK cell–based lysis of autologous Sézary cells, demonstrating both the functional integrity of …

WebInnate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the design of the “TELLOMAK” Phase II trial and new preclinical data supporting the potential of IPH4102 in peripheral T-cell lymphoma (“PTCL”) as well as Adult T-cell leukemia/lymphoma (“ATLL”) will be presented at the International Conference on … canada bakery deliveryWeb3 apr. 2024 · IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. … IPH4102 Alone or in Combination With Chemotherapy in Patients With … fish eat algaeWeb25 jun. 2024 · IPH4102 is a humanised, first-in-class, monoclonal antibody that targets KIR3DL2, a cell surface protein widely expressed in cutaneous T-cell lymphoma, and … canada background check privacy actWeb7 jun. 2024 · IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody that depletes KIR3DL2-expressing cells through antibody-dependent cell-cytotoxicity and … fish eat cerealWebIPH4102-201: National Competent Authority: Italy - Italian Medicines Agency: Clinical Trial Type: EEA CTA: Trial Status: Ongoing: Date on which this record was first entered in the … fish eat and grow videosWebTELLOMAK - IPH4102-201 T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of … fish eaten with bagels crosswordWebIPH4102 alleen of in combinatie met chemotherapie bij patiënten met gevorderd T-cellymfoom TELLOMAK: T-cellymfoom Anti-KIR3DL2-therapie. Een open label, … fish eat carrot